Clinical Trials Browser

Completed × OTHER × ublituximab × Clear all

NCT04508647 2024-03-21

Ublituximab Followed by Response-driven Addition of Umbralisib for Treatment-naive Follicular or Marginal Zone Lymphoma

Phase 2 Completed

4 enrolled 10 charts

Lymphoma, Follicular, Lymphoma, B-Cell, Marginal Zone

NCT02276963 2019-06-06

Ublituximab for Acute Neuromyelitis Optica (NMO) Relapses

Phase 1 Completed

6 enrolled 9 charts

Myelitis, Transverse, Neuromyelitis Optica, Optic Neuritis